Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
View original at globenewswire.comSutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Initial results from STRO-004 Phase 1 study expected in mid-2026
60% confidenceExploratory biomarker analyses suggest potential for STRO-004 combination studies addressing specific indications in either early or late lines of treatment
60% confidenceSTRO-004's favorable tolerability and pharmacokinetic profile are expected to enable increased drug exposure and payload delivery, supporting superior depth and durability of response in the clinic
60% confidenceSTRO-004 preclinical data underscore the potential of next-generation ADCs to drive meaningful activity across multiple solid tumors
60% confidencePreclinical data strengthen confidence in STRO-004's potential across indications and underscore platform versatility to generate differentiated ADCs across many targets and payloads
60% confidence